109 material Form 8-K filings that 99 companies we cover made with the SEC in June 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Acuity Brands reported fiscal third-quarter 2024 results for the quarter ended May 31, 2024. Net sales fell 3.2% from the prior year to $968.1 million, while diluted earnings per share rose 10.4% to $3.62 and operating profit rose 1.4%.
Net sales were $968.1 million, down $32.2 million or 3.2% from the prior-year quarter.
Diluted EPS was $3.62, up 10.4%; adjusted diluted EPS was $4.15, up 10.7% from $3.75.
Operating profit was $145.3 million, up 1.4%; adjusted operating profit was $167.1 million, up 2.6%.
Year-to-date operating cash flow was $445.1 million; the company repurchased about 454,000 shares for about $89 million.
Progress reported fiscal second-quarter 2024 revenue of $175.1 million, down 2% from a year earlier, while GAAP diluted earnings per share rose 37% to $0.37 and non-GAAP diluted EPS rose 3% to $1.09. The company said revenue and EPS were above the high end of its most recent guidance and raised its full-year 2024 revenue and EPS outlook, which matters to shareholders because it signals higher expected earnings even as sales declined.
Q2 revenue was $175.1 million, down 2% year over year; annualized recurring revenue was $579 million, up 1% on a constant currency basis.
GAAP diluted EPS was $0.37 versus $0.27 a year earlier; non-GAAP diluted EPS was $1.09 versus $1.06.
FY2024 GAAP diluted EPS guidance was raised to $1.98 to $2.10 from $1.94 to $2.06; non-GAAP EPS guidance was raised to $4.70 to $4.80 from $4.65 to $4.75.
FY2024 revenue guidance was raised to $725 million to $735 million from $722 million to $732 million.
At its June 14, 2024 annual meeting, TG Therapeutics stockholders approved raising authorized common stock from 175,000,000 to 190,000,000 shares and removing the full-value awards limit in the 2022 Incentive Plan. The company filed the charter amendment the same day, and all five proposals passed, although three director nominees received less than half of the votes cast for them. The larger share authorization gives the company room to issue more common stock, which could dilute existing holders.
Authorized common shares rise from 175,000,000 to 190,000,000; 73,780,225 votes for, 36,348,764 against, 946,040 abstentions.
2022 Incentive Plan amendment removing the full-value awards limit passed with 66,744,142 votes for and 8,625,685 against.
Advisory say-on-pay vote: 42,346,581 for, 31,019,084 against, 2,748,761 abstentions.
Yann Echelard (46.05%), Daniel Hume (46.03%) and Sagar Lonial, MD (43.75%) each received less than half of votes cast for them.
Core & Main reported fiscal first-quarter 2024 net sales up 10.6% to $1,741 million, driven mainly by acquisitions, while net income fell 24.1% to $101 million and diluted EPS fell 2.0% to $0.49. The company narrowed and raised its fiscal 2024 forecast for net sales and Adjusted EBITDA, but higher interest and SG&A costs and debt that rose to 2.7x Adjusted EBITDA leave the profit trend weaker than sales growth.
Net sales rose 10.6% to $1,741 million; net income fell 24.1% to $101 million
Diluted EPS fell 2.0% to $0.49 from $0.50; Adjusted EBITDA fell 1.4% to $217 million
Fiscal 2024 outlook now calls for net sales of $7.5 to $7.6 billion and Adjusted EBITDA of $935 to $975 million
Net Debt Leverage was 2.7x as of April 28, 2024, up 1.0x from a year earlier; five acquisitions closed during and after the quarter
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.